Fennec Pharmaceuticals Inc (FENC) financials
Fennec Pharmaceuticals revenue and earnings by year
Fennec Pharmaceuticals's revenue was $44.6 million in the fiscal year to December 31, 2025, down 6.1% from the year before. Net income was -$9.74 million, -21.8% of revenue. Since the fiscal year to December 31, 2020, revenue has grown 204.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|
| Revenue | 45 | 48 | 21 | 2 | 0 |
| Revenue growth | -6.1% | 123.7% | 1284.5% | 802.9% | — |
| Gross profit | 41 | 44 | 20 | 1 | — |
| Gross margin | 91.6% | 93.3% | 94.1% | 94.4% | — |
| Operating income | -6 | 3 | -13 | -23 | -18 |
| Operating margin | -14.1% | 5.4% | -60.1% | -1471.6% | -10520.6% |
| Net income | -10 | -0 | -16 | -24 | -18 |
| Net margin | -21.8% | -0.9% | -75.5% | -1544.9% | -10652.4% |
| Diluted EPS | -$0.34 | -$0.02 | -$0.60 | -$0.90 | -$0.76 |
| Free cash flow | -12 | 27 | -17 | -18 | -16 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open FENC in Markets.
How Fennec Pharmaceuticals makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Manufactured Product Other | $17.2M | 96.0% |
| Services & Other | $710K | 4.0% |
See also: FENC returns
No forecast, no recommendation. This page describes Fennec Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.